CN105241831A - Stable good-interference resistance serum zinc detection reagent and detection method - Google Patents
Stable good-interference resistance serum zinc detection reagent and detection method Download PDFInfo
- Publication number
- CN105241831A CN105241831A CN201510656657.8A CN201510656657A CN105241831A CN 105241831 A CN105241831 A CN 105241831A CN 201510656657 A CN201510656657 A CN 201510656657A CN 105241831 A CN105241831 A CN 105241831A
- Authority
- CN
- China
- Prior art keywords
- reagent
- serum zinc
- detects
- damping fluid
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 77
- 239000011701 zinc Substances 0.000 title claims abstract description 46
- 210000002966 serum Anatomy 0.000 title claims abstract description 42
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 229910052725 zinc Inorganic materials 0.000 title claims abstract description 39
- 238000001514 detection method Methods 0.000 title claims abstract description 17
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000004094 surface-active agent Substances 0.000 claims abstract description 14
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims abstract description 13
- 230000002421 anti-septic effect Effects 0.000 claims abstract description 9
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 9
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 9
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 9
- 239000000276 potassium ferrocyanide Substances 0.000 claims abstract description 9
- 239000011780 sodium chloride Substances 0.000 claims abstract description 9
- 239000001509 sodium citrate Substances 0.000 claims abstract description 9
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 claims abstract description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 9
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims abstract description 9
- 229940038773 trisodium citrate Drugs 0.000 claims abstract description 9
- 239000007983 Tris buffer Substances 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 7
- ZLLMYPVFZJLNKV-UHFFFAOYSA-M sodium 3-[3-hydroxy-4-[(5-nitropyridin-2-yl)diazenyl]-N-propylanilino]propane-1-sulfonate Chemical compound [Na+].CCCN(CCCS([O-])(=O)=O)c1ccc(N=Nc2ccc(cn2)[N+]([O-])=O)c(O)c1 ZLLMYPVFZJLNKV-UHFFFAOYSA-M 0.000 claims abstract description 5
- IYRGXJIJGHOCFS-UHFFFAOYSA-N neocuproine Chemical compound C1=C(C)N=C2C3=NC(C)=CC=C3C=CC2=C1 IYRGXJIJGHOCFS-UHFFFAOYSA-N 0.000 claims abstract description 4
- ORIHZIZPTZTNCU-YVMONPNESA-N salicylaldoxime Chemical compound O\N=C/C1=CC=CC=C1O ORIHZIZPTZTNCU-YVMONPNESA-N 0.000 claims abstract description 4
- 238000013016 damping Methods 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 14
- 229960003511 macrogol Drugs 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 7
- 239000011575 calcium Substances 0.000 abstract description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 239000010949 copper Substances 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 229910052802 copper Inorganic materials 0.000 abstract description 3
- 238000005336 cracking Methods 0.000 abstract description 3
- 229910052742 iron Inorganic materials 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 239000003381 stabilizer Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 239000000872 buffer Substances 0.000 abstract 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 abstract 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 abstract 1
- 229910001424 calcium ion Inorganic materials 0.000 abstract 1
- 229910001425 magnesium ion Inorganic materials 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 7
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to the technical field of serum zinc detection and especially relates to a serum zinc detection reagent. A reagent R1 contains a buffer, salicylaldoxime, dimethylglyoximate, a fluorocarbon surfactant FSO-300, 2, 9-dimethyl-1, 10-phenanthroline, ascorbic acid, potassium ferrocyanide, polyethylene glycol 6000, glycol, trisodium citrate, NaCl and an antiseptic. A reagent R2 contains a buffer, dimethyl sulfoxide, nitro-PAPS, a fluorocarbon surfactant FSO-300, ascorbic acid, potassium ferrocyanide, polyethylene glycol 6000, glycol, trisodium citrate, NaCl and an antiseptic. The Tris buffer, the stabilizing agent and a plurality of anti-interference agents are used, can effectively eliminate interference caused by copper, iron, calcium and magnesium ions and can substantially improve reagent stability. The used novel non-ionic fluorocarbon surfactant FSO-300 can promote serum zinc cracking, prevent reaction system turbidity, improve chromogenic substance stability, prevent a pretreatment process such as protein removal and substantially improve reagent sensitivity and stability.
Description
Technical field
The present invention relates to serum zinc detection technique field, particularly a kind of serum zinc detects reagent, also relates to the detection method using this to detect reagent.
Background technology
Zinc is that the mankind sustain life one of necessary trace element, and it is combined with albumin and enters blood after enteron aisle is absorbed by intestinal mucosa cells.Zinc is discharged primarily of in ight soil.The important physiological function of zinc is the co-factor maintaining multiple enzyme in human body, about has the metalloenzyme of more than 90 kinds must have the normal function of zinc competence exertion, such as erythrocytic carbonic anhydrase, alkaline phosphatase and synthesize relevant multiple enzyme etc. with DNA, RNA.Zinc plays an important role to the structure maintaining enzyme, and after being combined with memebrane protein, the structure of Absorbable organic halogens film, prevents film lipid peroxidation.
Zinc in food especially in fish, eggs and cheese content very abundant.Zinc is the nutrient that body weight for humans is wanted, and its english abbreviation is: Zn.Zn content relative constancy in normal human blood, content is about 0.6 ~ 1.2mg/L.Serum zinc reduction sees acute myocardial infarction AMI, acute organ burn, hepatopathy, kidney trouble, diabetes etc.Serum zinc raises and sees hyperthyroidism, hypophysis and hypoadrenocorticism, polycythemia vera, eosinophilia, hyperpietic.
At present, the detection method that serum zinc is conventional has compleximetry, fluorimetry, colourimetry, atomic absorption spectrophotometry etc., and compleximetry sample consumption is large, and waste time and energy, specificity is low.Although fluorimetry is simple to operate, need specific instrument-fluorophotometer.And
Atomic absorption spectrophotometry specificity is high, simple to operate, but instrument is very expensive, is difficult to universal at basic hospital.
Given this, the present invention adopts colourimetry, and this method is simple to operate, quick, highly sensitive, is applicable to automated analysis.By optimizing reaction system, the isoionic interference of iron, copper, calcium, magnesium effectively can be avoided.Add the stability that stabilizing agent Macrogol 6000, ethylene glycol, NaCl etc. effectively can improve reagent; And preferred nonionic fluorocarbon surfactant FSO-300 adds the cracking that can promote serum zinc, reaction system can be prevented muddy, strengthen the stability of substance that show color, avoid the pre-treatment step such as removing protein.Significantly improve the sensitivity of reagent, fast easy and simple to handle, being applicable to automated analysis, is a kind of more stable, serum zinc (Zn) reagent that antijamming capability is strong.
Summary of the invention
The object of this invention is to provide one for detecting the reagent of serum zinc (Zn) and using this reagent to detect the method for serum zinc content.This kit adopts colourimetry, effectively can detect the content of serum zinc, and antijamming capability is strong, the advantages such as good stability.
Ultimate principle:
Nitro-PAPS reacts with Zn in alkaline solution, and raw empurpled compound, has maximum absorption peak at 570nm place.The interference of copper ion can by adding preferred neocuproine-2, and 9-dimethyl-1,10-phenanthroline is removed; The interference of ferric ion can by adding the elimination such as ascorbic acid and potassium ferrocyanide; And the earth alkali metal such as calcium, magnesium can eliminate its interference by adding trisodium citrate etc.
The present invention is obtained by following steps:
A kind of serum zinc detects reagent, and comprise reagent R1 and reagent R2, described reagent R1's and reagent R2 is composed as follows:
The component of reagent R1 is:
Damping fluid
200mmol/L,
Salicylaldoxime
5mmol/L,
Dimethylglyoximate
2mmol/L,
Fluorocarbon surfactant FSO-300
10ml/L,
2,9-dimethyl-1,10-phenanthroline
3mmol/L,
Ascorbic acid
5mmol/L,
Potassium ferrocyanide
1mmol/L,
Macrogol 6000
10g/L,
Ethylene glycol
5ml/L,
Trisodium citrate
12g/L,
NaCl
···················································································9g/L，
Antiseptic
0.5g/L;
The component of reagent R2 is:
Damping fluid
200mmol/L,
Dimethyl sulfoxide (DMSO)
5ml/L,
Nitro-PAPS
0.5mmol/L,
Fluorocarbon surfactant FSO-300
10ml/L,
Ascorbic acid
5mmol/L,
Potassium ferrocyanide
1mmol/L,
Macrogol 6000
10g/L,
Ethylene glycol
5ml/L,
Trisodium citrate
12g/L,
NaCl
···················································································9g/L，
Antiseptic
0.5g/L.
Described serum zinc detects reagent, and in reagent R1, damping fluid is 25 DEG C, and pH is the Tris damping fluid of 8.2.
Described serum zinc detects reagent, and in reagent R2, damping fluid is 25 DEG C, and pH is the Tris damping fluid of 8.2.
Described serum zinc detects reagent, and described antiseptic is NaN
3.
Described serum zinc detects the detection method that reagent detects serum zinc content, and use automatic clinical chemistry analyzer to utilize end-point method to measure, detection predominant wavelength is 570nm.
Described detection method, the ratio of R1 reagent and R2 reagent is 4:1.
Beneficial effect of the present invention:
1) adopt new buffer system and stabilizing agent and add multiple anti-interference agent, effectively can remove copper, iron and calcium, the isoionic interference of magnesium, significantly improve the stability of reagent;
2) adopt new non-ionic type fluorocarbon surfactant FSO-300, the cracking of serum zinc can be promoted, reaction system can be prevented muddy, strengthen the stability of substance that show color, avoid the pre-treatment step such as removing protein, significantly improve sensitivity and the stability of reagent;
3) reagent accuracy and have good stability, low price, easy to use, can meet clinical needs completely.
Accompanying drawing explanation
Fig. 1 is the correlation curve figure of two kinds of reagent;
Fig. 2 is two kinds of reagent effect phase stability curve figure;
Fig. 3 embodiment 1 reagent test method;
Fig. 4 embodiment 1 reagent interference free performance compares;
Fig. 5 embodiment 1 reagent and market is common and the Determination of Zn in Serum kit got the nod contrasts testing result.
Embodiment
Below in conjunction with specific embodiment, the present invention is further described.
embodiment 1
The detection reagent of serum zinc, bag reagent R1 and reagent R2:
1) the consisting of of its R1:
Tris(trishydroxymethylaminomethane) damping fluid (pH=8.2,25 DEG C)
100mmol/L
Salicylaldoxime
5mmol/L,
Dimethylglyoximate
2mmol/L,
Fluorocarbon surfactant FSO-300
10ml/L,
2,9-dimethyl-1,10-phenanthroline
3mmol/L,
Ascorbic acid
5mmol/L,
Potassium ferrocyanide
1mmol/L,
Macrogol 6000
10g/L,
Ethylene glycol
5ml/L,
Trisodium citrate
12g/L,
NaCl
··················································································································9g/L，
Liquid BPF aN
30.5g/L
2) component of reagent R2 is:
Tris(trishydroxymethylaminomethane) damping fluid (pH=8.2,25 DEG C)
100mmol/L
Dimethyl sulfoxide (DMSO)
5ml/L,
Nitro-PAPS
0.5mmol/L,
Fluorocarbon surfactant FSO-300
10ml/L,
Ascorbic acid
5mmol/L,
Potassium ferrocyanide
1mmol/L,
Macrogol 6000
10g/L,
Ethylene glycol
5ml/L,
Trisodium citrate
12g/L,
NaCl
··············································································································9g/L，
Antiseptic
0.5g/L,
Liquid BPF aN
30.5g/L.
3) using method of the present embodiment reagent:
The serum zinc that the present embodiment describes detects reagent, adopts the automatic clinical chemistry analyzer with double reagent function in use, as Hitachi 7180 fully-automatic analyzer etc., utilizes end-point method to measure.Be placed on corresponding reagent position according to the ratio of 4:1 by R1 and R2, place distilled water, standard items and sample at the correspondence position of sample disc, operation is as Fig. 3:
calculate: serum zinc content (μ
mol/L)=(A measures ÷ A standard) × C standard.
embodiment 2
Interference is tested: get fresh mix serum, be divided into 2 equal portions, then every equal portions are divided into 7 equal portions again, add different interfering materials, makes its concentration in serum reach the requirement of Fig. 4.Then use embodiment 1 gained reagent respectively, and the serum zinc approved (Zn) reagent common with market is the content of Zn in comparative determination serum simultaneously, control group measurement result with add disturbance material after the measurement result respectively organized see Fig. 4.Mensuration average × 100% of relative deviation (%)=(the mensuration average of the mensuration average-check sample of interference sample)/check sample.
As seen from Figure 4, embodiment 1 reagent is at triglyceride≤1000mg/dL, cholerythrin≤50mg/dL, Cu
2+≤ 60 μm of ol/L, Fe
3+≤ 60 μm of ol/L, Ca
2+≤ 5mmol/L, Mg
2+≤ 4mmol/L does not obviously disturb test result.And control group reagent is when above-mentioned concentration interfering material exists, be subject to obvious interference, this illustrates that the interference free performance of embodiment 1 reagent significantly improves, and is far superior to contrast agent by after optimization reaction buffer system, interpolation anti-interference agent and nonionic fluorocarbon surfactant FSO-300.
embodiment 3
Correlativity is tested: utilize embodiment 1 formulated reagent, the serum zinc kit of certain company that the State Food and Drug Administration common with market is approved carries out control test, and have detected 20 clinical serum samples, testing result as shown in Figure 5 simultaneously.And obtain the correlation curve (as shown in Figure 1) of two kinds of reagent, shown by testing result, the related coefficient of two kits is 0.9994, and describing both has great correlativity.
embodiment 4
The stability contrast test of reagent: to the reagent in embodiment 1, even packing 13 groups, the amount of reagent often organized is R1 be 20mL, R2 is 5mL; And serum zinc (Zn) kit getting certain company of the common State Food and Drug Administration's accreditation in 13 groups of market compares.Be placed in 2-8 DEG C of refrigerator, a taking-up on the same day group reagent monthly detects Zn quality-control product, and (target value is 19.5
μm ol/L), as shown in Figure 2, it is more stable that the serum zinc (Zn) more common than market under 2-8 DEG C of condition of storage of embodiment 1 reagent measures kit to testing result.
By checking, it is good that this reagent and similar detection reagent contrast correlativity, and clinical detection sample results is consistent, can reach the application requirement of market to product, and good in anti-interference performance is that a kind of more stable, good serum zinc (Zn) detects reagent.
Claims (7)
1. serum zinc detects a reagent, and it is characterized in that comprising reagent R1 and reagent R2, described reagent R1's and reagent R2 is composed as follows:
The component of reagent R1 is:
Damping fluid
200mmol/L,
Salicylaldoxime
5mmol/L,
Dimethylglyoximate
2mmol/L,
Fluorocarbon surfactant FSO-300
10ml/L,
2,9-dimethyl-1,10-phenanthroline
3mmol/L,
Ascorbic acid
5mmol/L,
Potassium ferrocyanide
1mmol/L,
Macrogol 6000
10g/L,
Ethylene glycol
5ml/L,
Trisodium citrate
12g/L,
NaCl
···················································································9g/L，
Antiseptic
0.5g/L;
The component of reagent R2 is:
Damping fluid
200mmol/L,
Dimethyl sulfoxide (DMSO)
5ml/L,
Nitro-PAPS
0.5mmol/L,
Fluorocarbon surfactant FSO-300
10ml/L,
Ascorbic acid
5mmol/L,
Potassium ferrocyanide
1mmol/L,
Macrogol 6000
10g/L,
Ethylene glycol
5ml/L,
Trisodium citrate
12g/L,
NaCl
···················································································9g/L，
Antiseptic
0.5g/L.
2. serum zinc according to claim 1 detects reagent, and it is characterized in that in reagent R1, damping fluid is 25 DEG C, pH is the Tris damping fluid of 8.2.
3. serum zinc according to claim 1 detects reagent, and it is characterized in that in reagent R1, damping fluid is 25 DEG C, pH is the Tris damping fluid of 8.2.
4. serum zinc according to claim 1 detects reagent, it is characterized in that in reagent R1 and R2, surfactant is fluorocarbon surfactant FSO-300.
5. serum zinc according to claim 1 detects reagent, it is characterized in that described antiseptic is NaN
3.
6. the serum zinc according to any one of claim 1-5 detects the detection method that reagent detects serum zinc, it is characterized in that using automatic clinical chemistry analyzer to utilize end-point method to measure, and detection predominant wavelength is 570nm.
7. detection method according to claim 6, is characterized in that the ratio of R1 reagent and R2 reagent is 4:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510656657.8A CN105241831A (en) | 2015-10-12 | 2015-10-12 | Stable good-interference resistance serum zinc detection reagent and detection method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510656657.8A CN105241831A (en) | 2015-10-12 | 2015-10-12 | Stable good-interference resistance serum zinc detection reagent and detection method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105241831A true CN105241831A (en) | 2016-01-13 |
Family
ID=55039553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510656657.8A Pending CN105241831A (en) | 2015-10-12 | 2015-10-12 | Stable good-interference resistance serum zinc detection reagent and detection method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105241831A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106370862A (en) * | 2016-08-30 | 2017-02-01 | 山东博科生物产业有限公司 | Stable and sensitive fibronectin detection reagent |
| CN107290522A (en) * | 2017-06-15 | 2017-10-24 | 中国农业大学 | A kind of kit of zinc ion content quick detection |
| CN108169224A (en) * | 2017-12-27 | 2018-06-15 | 山东博科生物产业有限公司 | A kind of serum magnesium detection reagent and preparation |
| CN108444805A (en) * | 2018-02-13 | 2018-08-24 | 广州聚佰生物科技有限公司 | A kind of purifying tablets for rapid detection for pesticide residue pre-treatment |
| CN109374884A (en) * | 2018-12-24 | 2019-02-22 | 四川沃文特生物技术有限公司 | A kind of PCT concentration detection kit and preparation method thereof |
| CN112858422A (en) * | 2019-11-12 | 2021-05-28 | 北京怡成生物电子技术股份有限公司 | Electrochemical uric acid test strip for removing interference of ascorbic acid and manufacturing and application thereof |
| CN112986223A (en) * | 2021-02-25 | 2021-06-18 | 吉林大学第一医院 | Reagent strip for rapid detection of seminal plasma biochemical zinc ions |
| CN114705640A (en) * | 2021-01-01 | 2022-07-05 | 桂林优利特医疗电子有限公司 | High-sensitivity serum zinc determination reagent with strong anti-interference capability and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002086512A2 (en) * | 2001-04-24 | 2002-10-31 | Axis-Shield Asa | Haemoglobin assay |
| CN1635379A (en) * | 2004-11-30 | 2005-07-06 | 曹建明 | Serum copper, iron and zinc rapid sensitive detection kit and preparing method thereof |
| CN101097220A (en) * | 2006-06-28 | 2008-01-02 | 温州医学院 | Blood serum copper, zincium and iron 5-br-padcap even phase automatic analysis method and liquid stabilizing reagent |
| CN101263247A (en) * | 2005-09-20 | 2008-09-10 | 埃其玛公司 | Electroplating composition for coating a substrate surface with a metal |
| CN101310184A (en) * | 2005-11-14 | 2008-11-19 | 拜尔健康护理有限责任公司 | Test sensor reagent with cellulose polymer |
| CN101389954A (en) * | 2006-02-23 | 2009-03-18 | 世诺临床诊断制品株式会社 | Colorimetric determination method and determination reagent for metal |
| CN104483494A (en) * | 2014-12-22 | 2015-04-01 | 宁波美康生物科技股份有限公司 | Serum UIBC (unsaturated iron bonding capacity) detection kit |
-
2015
- 2015-10-12 CN CN201510656657.8A patent/CN105241831A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002086512A2 (en) * | 2001-04-24 | 2002-10-31 | Axis-Shield Asa | Haemoglobin assay |
| CN1635379A (en) * | 2004-11-30 | 2005-07-06 | 曹建明 | Serum copper, iron and zinc rapid sensitive detection kit and preparing method thereof |
| CN101263247A (en) * | 2005-09-20 | 2008-09-10 | 埃其玛公司 | Electroplating composition for coating a substrate surface with a metal |
| CN101310184A (en) * | 2005-11-14 | 2008-11-19 | 拜尔健康护理有限责任公司 | Test sensor reagent with cellulose polymer |
| CN101389954A (en) * | 2006-02-23 | 2009-03-18 | 世诺临床诊断制品株式会社 | Colorimetric determination method and determination reagent for metal |
| CN101097220A (en) * | 2006-06-28 | 2008-01-02 | 温州医学院 | Blood serum copper, zincium and iron 5-br-padcap even phase automatic analysis method and liquid stabilizing reagent |
| CN104483494A (en) * | 2014-12-22 | 2015-04-01 | 宁波美康生物科技股份有限公司 | Serum UIBC (unsaturated iron bonding capacity) detection kit |
Non-Patent Citations (2)
| Title |
|---|
| 连国军 等: "Nitro-PAPS直接光度法测定血清锌", 《临床检验杂志》 * |
| 连国军: "血清铜、锌、铁均相自动化检测技术的研究", 《万方学位论文》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106370862A (en) * | 2016-08-30 | 2017-02-01 | 山东博科生物产业有限公司 | Stable and sensitive fibronectin detection reagent |
| CN106370862B (en) * | 2016-08-30 | 2018-07-20 | 山东博科诊断科技有限公司 | A kind of stabilization, sensitive fibronectin detection reagent |
| CN107290522A (en) * | 2017-06-15 | 2017-10-24 | 中国农业大学 | A kind of kit of zinc ion content quick detection |
| CN108169224A (en) * | 2017-12-27 | 2018-06-15 | 山东博科生物产业有限公司 | A kind of serum magnesium detection reagent and preparation |
| CN108444805A (en) * | 2018-02-13 | 2018-08-24 | 广州聚佰生物科技有限公司 | A kind of purifying tablets for rapid detection for pesticide residue pre-treatment |
| CN108444805B (en) * | 2018-02-13 | 2020-10-02 | 广州聚佰生物科技有限公司 | Purifying sheet for quick pesticide residue detection pretreatment |
| CN109374884A (en) * | 2018-12-24 | 2019-02-22 | 四川沃文特生物技术有限公司 | A kind of PCT concentration detection kit and preparation method thereof |
| CN112858422A (en) * | 2019-11-12 | 2021-05-28 | 北京怡成生物电子技术股份有限公司 | Electrochemical uric acid test strip for removing interference of ascorbic acid and manufacturing and application thereof |
| CN112858422B (en) * | 2019-11-12 | 2022-12-20 | 北京怡成生物电子技术股份有限公司 | Electrochemical uric acid test strip for removing interference of ascorbic acid and manufacturing and application thereof |
| CN114705640A (en) * | 2021-01-01 | 2022-07-05 | 桂林优利特医疗电子有限公司 | High-sensitivity serum zinc determination reagent with strong anti-interference capability and preparation method thereof |
| CN112986223A (en) * | 2021-02-25 | 2021-06-18 | 吉林大学第一医院 | Reagent strip for rapid detection of seminal plasma biochemical zinc ions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105241831A (en) | Stable good-interference resistance serum zinc detection reagent and detection method | |
| Chung et al. | Plasma ascorbic acid: measurement, stability and clinical utility revisited | |
| CN104988207B (en) | The α-hydroxybutyrate dehydrogenase reagent and detection method of a kind of stabilization, strong antijamming capability | |
| CN106383116B (en) | A kind of kit detecting high-density lipoprotein cholesterol | |
| CN103760357B (en) | A kind of ischemia modified albumin IMA detection kit | |
| CN101458257B (en) | Kit for detecting ischemia modified albumin and method for making same | |
| JP6397907B2 (en) | Method for diagnosing primary hyperaldosteronism | |
| CN105420345A (en) | Stable serum 5'-ribotide hydrolase detection reagent with strong anti-interference capability and detection method | |
| CN105543336A (en) | A stable serum phospholipid detecting reagent high in interference-resisting capability and a detecting method | |
| CN109991177A (en) | A kind of stabilization, bilirubin direct (enzymatic measurement) detection reagent of strong antijamming capability and detection method | |
| CN104931448B (en) | A kind of detection reagent and its detection method of lactate dehydrogenase isoenzyme 1 | |
| CN104406971A (en) | Direct bilirubin detection reagent | |
| CN104374905A (en) | Serum creatine kinase detection reagent | |
| US20180027802A1 (en) | Composition and use of substances for the in vitro stabilization of glucose, lactate and homocysteine in blood | |
| CN101776692A (en) | Kit for detecting total bilirubin by using vanadate oxidation method | |
| CN106868096A (en) | A kind of stability is strong and hexokinase method glucose determination reagent of low cost | |
| CN104359846A (en) | Kit for detecting content of alpha-L-fucosidase | |
| EP3146336B1 (en) | Storage device, system and method for determining the metabolic state of red blood cells and platelets | |
| CN106404686A (en) | Antiheparin serum total bilirubin (vanadate oxidation method) detection kit | |
| CN105424934A (en) | N-acetyl-beta-D glucosidase reagent and detection method | |
| Ivanova et al. | HPLC determination of plasma dimethylarginines: method validation and preliminary clinical application | |
| WO2003069344A1 (en) | Anti-glycolytic composition | |
| CN108169224A (en) | A kind of serum magnesium detection reagent and preparation | |
| Vichapong et al. | Alternative spectrophotometric method for determination of bilirubin and urobilinogen in urine samples using simultaneous injection effective mixing flow analysis | |
| Treberg et al. | Vanadium accumulation in ascidian coelomic cells is associated with enhanced pentose phosphate pathway capacity but not overall aerobic or anaerobic metabolism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160113 |
|
| WD01 | Invention patent application deemed withdrawn after publication |